These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 16815286)
1. Systemic absorption of 5-fluorouracil during vitrectomy. Creten O; Spileers W; Stalmans P Am J Ophthalmol; 2006 Jul; 142(1):194-6. PubMed ID: 16815286 [TBL] [Abstract][Full Text] [Related]
2. Systemic resorption of 5-fluorouracil used in infusion fluid during vitrectomy. Creten O; Spileers W; Stalmans P Bull Soc Belge Ophtalmol; 2007; (303):37-41. PubMed ID: 17894285 [TBL] [Abstract][Full Text] [Related]
3. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of alpha-fluoro-beta-alanine in urine. Sessink PJ; Timmersmans JL; Anzion RB; Bos RP J Occup Med; 1994 Jan; 36(1):79-83. PubMed ID: 8138854 [TBL] [Abstract][Full Text] [Related]
4. Assay of urinary alpha-fluoro-beta-alanine by gas chromatography-mass spectrometry for the biological monitoring of occupational exposure to 5-fluorouracil in oncology nurses and pharmacy technicians. Rubino FM; Verduci C; Buratti M; Fustinoni S; Campo L; Omodeo-Salè E; Giglio M; Iavicoli S; Brambilla G; Colombi A Biomed Chromatogr; 2006 Mar; 20(3):257-66. PubMed ID: 16167301 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Wickham L; Bunce C; Wong D; McGurn D; Charteris DG Ophthalmology; 2007 Apr; 114(4):698-704. PubMed ID: 17398320 [TBL] [Abstract][Full Text] [Related]
6. Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. Thiberville L; Compagnon P; Moore N; Bastian G; Richard MO; Hellot MF; Vincent C; Kannass MM; Dominique S; Thuillez C Cancer Chemother Pharmacol; 1994; 35(1):64-70. PubMed ID: 7987979 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy]. Bi HS; Cui Y; Zhang JH; Wang XR; Xie XF Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):37-41. PubMed ID: 16638279 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs. Schmidt Laugesen C; Steffansen B; Scherfig E; la Cour M Acta Ophthalmol Scand; 2005 Apr; 83(2):184-90. PubMed ID: 15799730 [TBL] [Abstract][Full Text] [Related]
9. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. Ozaki Y; Imamaki H; Ikeda A; Oura M; Nakagawa S; Funakoshi T; Kataoka S; Nishikawa Y; Horimatsu T; Yonezawa A; Matsubara T; Yanagita M; Muto M; Watanabe N Cancer Chemother Pharmacol; 2020 Nov; 86(5):693-699. PubMed ID: 33011861 [TBL] [Abstract][Full Text] [Related]
10. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy. Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114 [TBL] [Abstract][Full Text] [Related]
11. Decreased vitreal hyaluronan levels with aging. Itakura H; Kishi S; Kotajima N; Murakami M Ophthalmologica; 2009; 223(1):32-5. PubMed ID: 18953185 [TBL] [Abstract][Full Text] [Related]
12. Vitreous proteomic analysis of proliferative vitreoretinopathy. Yu J; Liu F; Cui SJ; Liu Y; Song ZY; Cao H; Chen FE; Wang WJ; Sun T; Wang F Proteomics; 2008 Sep; 8(17):3667-78. PubMed ID: 18752205 [TBL] [Abstract][Full Text] [Related]
13. Incidence of endophthalmitis after 20- and 25-gauge vitrectomy causes and prevention. Shimada H; Nakashizuka H; Hattori T; Mori R; Mizutani Y; Yuzawa M Ophthalmology; 2008 Dec; 115(12):2215-20. PubMed ID: 18930557 [TBL] [Abstract][Full Text] [Related]
14. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy. Quiram PA; Gonzales CR; Hu W; Gupta A; Yoshizumi MO; Kreiger AE; Schwartz SD Ophthalmology; 2006 Nov; 113(11):2041-7. PubMed ID: 16952397 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo. Zheng H; Wang Z; Wang P; Liu Y; Jiang Z; Gao Q Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):751-9. PubMed ID: 22119880 [TBL] [Abstract][Full Text] [Related]
17. Biomonitoring of occupational exposure to 5-FU by assaying α-fluoro-β-alanine in urine with a highly sensitive UHPLC-MS/MS method. Dhersin A; Atgé B; Martinez B; Titier K; Rousset M; Sidatt Cheikh El Moustaph M; Verdun-Esquer C; Molimard M; Villa A; Canal-Raffin M Analyst; 2018 Aug; 143(17):4110-4117. PubMed ID: 30058665 [TBL] [Abstract][Full Text] [Related]
18. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Yeh PT; Yang CM; Huang JS; Chien CT; Yang CH; Chiang YH; Shih YF Ophthalmology; 2008 Apr; 115(4):734-737.e1. PubMed ID: 18177940 [TBL] [Abstract][Full Text] [Related]
19. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Banerjee S; Savant V; Scott RA; Curnow SJ; Wallace GR; Murray PI Invest Ophthalmol Vis Sci; 2007 May; 48(5):2203-7. PubMed ID: 17460280 [TBL] [Abstract][Full Text] [Related]
20. [Advantages and disadvantages of the circumferential retinal cryocoagulation before vitrectomy in proliferative diabetic vitreoretinopathy]. Schulze S; Zaki N; Kroll P Klin Monbl Augenheilkd; 2007 Aug; 224(8):647-52. PubMed ID: 17717781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]